다발성 골수종 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 치료법별, 유통경로별, 지역별 - 업계 예측(2026-2033년)

Multiple Myeloma Market size was valued at USD 29.12 Billion in 2024 and is poised to grow from USD 33.52 Billion in 2025 to USD 103.25 Billion by 2033, growing at a CAGR of 15.1% during the forecast period (2026-2033).

The increasing prevalence of multiple myeloma and heightened investment in oncology research are set to drive market growth. Innovations in cancer therapies, particularly the rising adoption of CAR-T cell therapy, monoclonal antibodies, and immune checkpoint inhibitors, will benefit industry players. Significant investments in the research and development of treatments and diagnostics, along with the escalating emphasis on personalized medicine, present new opportunities for companies in this sector. Increased initiatives to raise awareness of multiple myeloma and efforts to promote early diagnosis will further expand the market for providers. However, high treatment costs, the potential for adverse effects, lack of awareness, and the emergence of treatment resistance pose challenges that may restrict the positive market outlook over the long term.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Myeloma Market Segments Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs,Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Multiple Myeloma Market

The growing global population of older individuals is poised to significantly elevate the demand for multiple myeloma treatments, acting as a crucial driver for the market. Research indicates that aging adults are at a higher risk of developing multiple myeloma, consequently influencing the expansion of the market. As the prevalence of this condition rises with age, the need for effective therapies and management solutions is expected to increase, thereby propelling market growth. This demographic shift underscores the urgency for advancements in treatments and resources dedicated to addressing the unique challenges presented by multiple myeloma in older populations.

Restraints in the Multiple Myeloma Market

The treatment landscape for multiple myeloma predominantly features chemotherapy, immunotherapy, and stem cell transplants; however, these approaches come with significant risks of adverse effects, including neuropathy, infections, and gastrointestinal complications. Such severe side effects can discourage patients from pursuing treatment options, ultimately hindering the demand for therapies within the multiple myeloma market. As potential patients weigh the benefits against the potential for debilitating repercussions, the overall acceptance of available treatment modalities may diminish, posing a substantial challenge to the growth and advancement of multiple myeloma therapies. This restraint highlights the need for safer, more tolerable treatment alternatives in this field.

Market Trends of the Multiple Myeloma Market

The market for multiple myeloma is increasingly shifting towards personalized medicine, reflecting a growing awareness and demand among patients for tailored treatment options. This trend allows healthcare providers to customize therapies based on individual genetic profiles and biomarker analysis, significantly enhancing treatment efficacy while minimizing adverse effects. By adopting a personalized medicine approach, companies can improve patient outcomes and quality of life, fostering loyalty and preference among consumers. As the emphasis on targeted therapies continues to rise, stakeholders within the multiple myeloma sector are positioned to innovate and differentiate their offerings to meet the evolving needs of patients in a competitive landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• Value Chain Analysis
• Raw Material Analysis
• Pricing Analysis
• Consumer Behaviour Analysis
• PESTLE Analysis

Multiple Myeloma Market, By Drug Class

• Market Overview
• Proteasome Inhibitors
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Steroids

Multiple Myeloma Market, By Therapy

• Market Overview
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Multiple Myeloma Market Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (Bristol-Myers Squibb Company) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONO Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Oncology (Millennium Pharmaceuticals) (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments